# A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes

> **NCT02033239** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 46 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Faster-acting insulin aspart
- **DRUG:** insulin aspart

## Key facts

- **NCT ID:** NCT02033239
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2017-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02033239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02033239, "A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02033239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*